At what enterprise value was NEMERA acquired in 2014?

During the acquisition of NEMERA by MONTAGU PRIVATE EQUITY in 2014, the transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b EUR.

What was the EV/EBITDA of NEMERA when it was acquired by MONTAGU PRIVATE EQUITY?

The estimated EV/EBITDA multiple for NEMERA is in the range of 5x - 12x.

When was NEMERA acquired by MONTAGU PRIVATE EQUITY?

NEMERA was acquired by MONTAGU PRIVATE EQUITY in 2014.

What was the revenue of NEMERA at the time of the deal?

The revenue of NEMERA at the time of the deal is estimated to be in the range of 250M - 500M EUR.

What was the EBITDA of NEMERA during the acquisition?

NEMERA's EBITDA is estimated to be in the range of 50M - 100M EUR.

How is the data for the NEMERA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the NEMERA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://montagu.com/case-studies/nemera/

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaNEMERA

02/2014

NEMERA acquired by MONTAGU PRIVATE EQUITY

FRANCE Life Sciences / Medical Devices / Medical Consumables EV 500M - 1.5b EUR

Context

The deal involves the carve-out of Rexam's healthcare devices and prescription retail divisions, which will be acquired by Montagu Private Equity. The transaction is subject to regulatory approval and is expected to be completed in the coming weeks. The strategic rationale behind the deal is to create a standalone company that can focus on the healthcare sector and leverage Montagu Private Equity's expertise and resources to drive growth and expansion. The deal is expected to enhance the competitiveness of the company and improve its market position, while also providing opportunities for innovation and investment in new products and technologies. The company's management team will work closely with Montagu Private Equity to develop a growth strategy that builds on the company's strengths and addresses the evolving needs of the healthcare market. With a strong foundation in place, the company is well-positioned to capitalize on emerging trends and opportunities in the healthcare sector, including the growing demand for innovative medical devices and pharmaceutical packaging solutions.

NEMERA, which reported an EBITDA margin of in 2013, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Nemera (ex Rexam Healthcare Devices and Prescription Retail) is a leading provider of healthcare devices and pharmaceutical packaging solutions. The company's healthcare devices division designs and manufactures a range of products, including inhalers for asthma, insulin pens, and nasal pumps. The prescription retail division produces flacons and security caps for medications sold in pharmacies. With a strong presence in Europe and the United States, the company has a diverse portfolio of products that cater to various healthcare markets, including pulmonary, parenteral, ENT, dermal, and ophthalmic. The company's products are designed to improve patient outcomes and enhance the overall quality of healthcare. With a rich history and a strong commitment to innovation, Rexam Healthcare Devices and Prescription Retail has established itself as a trusted partner in the healthcare industry.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2013

2012

Other operations with NEMERA

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
08/2025	LGT CAPITAL PARTNERS	NEMERA	FRANCE	Medical Consumables
10/2018	ASTORG	NEMERA	FRANCE	Medical Consumables

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 250M - 500M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NEMERA by MONTAGU PRIVATE EQUITY are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: nemera

Acquirer: montagu private equity